Psychedelics in Multiple Sclerosis: Mechanisms, Challenges, and Prospects for Neuroimmune Modulation and Repair.

Psychedelic compounds that activate the 5-HT2A receptor might help treat multiple sclerosis by both calming harmful inflammation and promoting repair in the brain and spinal cord. Current MS drugs work on the immune system but do little to fix damage inside the central nervous system. Psychedelics appear to reduce pro-inflammatory signals from glial cells while increasing factors that support nerve cell health and myelin repair. However, most evidence comes from studies of general inflammation, not autoimmune disease, so it is unclear if these effects will work for MS. Major obstacles include heart and mental health risks, plus legal and ethical barriers. The authors suggest that non-hallucinogenic drugs inspired by psychedelics, which activate the same receptor without the mind-altering effects, may be a more practical path forward.

Study at a glance

Abstract

Multiple Sclerosis (MS) therapies effectively modulate peripheral immune responses but largely fail to promote neural repair within the central nervous system. This review evaluates whether psychedelic compounds (PSYs), via 5-HT2A activation, can fill a critical therapeutic gap: the need for agents that simultaneously suppress neuroinflammation and promote regeneration. We dissect the evidence suggesting PSYs can reprogram the neuroimmune milieu by downregulating key pro-inflammatory cytokines (e.g., TNF-α, IL-6) in glial cells while concurrently upregulating crucial neurotrophic factors (e.g., BDNF) that promote synaptic plasticity and oligodendrocyte support. However, we argue that the current evidence, largely derived from non-specific inflammation models, is insufficient to predict clinical efficacy in an autoimmune disease like MS. We critically analyze the significant translational barriers-from cardiovascular and psychiatric risks to profound legal and ethical challenges-that temper the immediate clinical promise. Finally, we propose a forward-looking perspective, suggesting that the true value of PSYs may lie not in their direct clinical use, but in uncovering novel therapeutic pathways. The emergence of non-hallucinogenic, functionally selective 5-HT2A agonists, inspired by psychedelic pharmacology, represents a more viable strategy to harness these mechanisms for MS therapy, demanding rigorous preclinical validation in disease-relevant models.